**Other Indications for Liver Transplantation**

248 Liver Transplantation – Basic Issues

Stangl, J.R., Carroll, K.L., Illichmann, M. & Striker, R. (2004). Effect of antimetabolite

Stravitz, R.T., Shiffman, M.L., Sanyal, A.J., Luketic, V.A., Sterling, R.K., Heuman, D.M.,

Takaki, A., Yagi, T., Iwasaki, Y., Sadamori, H., Matsukawa, H., Matsuda, H., Shinoura, S.,

liver transplantation. *Transplantation*, Vol.83, No.2 (January 2007), 231–3 Terrault, N., Roche, B. & Samuel, D. (2005). Management of the hepatitis B virus in the liver

Terrault, N.A. (2003). Prophylactic and preemptive therapies for hepatitis C virus-infected

Verna, E.C. & Brown, R.S.Jr. (2008). Hepatitis C and liver transplantation: enhancing

Villeneuve, J.P., Durantel, D., Durantel, S., Westland, C., Xiong S., Brosgart C.L., Gibbs, C.S.,

Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. (2003). Cyclosporin A

Wiesner, R.H., Sorrell, M. & Villamil, F. (2003) Report of the first International Liver

and hepatitis C. *Liver Transplantation*, Vol.9, No.11, (November 2003), S1–S9 Yeo, W., Hui, E.P., Chan, A.T., Wong, W.L., Ho, W.M., Lam, K.C. & Johnson, P.J. (2004).

Zimmerman, M.A. & Ghobrial, R.M. (2005). When should't we retransplant? *Liver* 

Zoulim, F., Radenne, S. & Ducerf, C. (2008). Management of patients with decompensated

*Transplantation*, Vol.11, Suppl.2, (November 2005), S14–S20

Vol.77, No.4, (February 2004), 562–7

*Transplantation*, Vol.10, No.7, (July 2004), 850–8

*Transplantation*, Vol.11, No.7, (July 2005), 716–32

(November 2003), S95 – S100

No.3, (August 2008), 637–59

(October 2008), S1–S7

Vol.39, No.6, (December 2003), 1085–9

*Hepatology*, Vol.38, No.5, (November 2003),1282–8

*of Cancer*, Vol.90, No.7, (April 2004), 1306–11

immunosuppressants on Flaviviridae, including hepatitis C virus. *Transplantation*,

Ashworth, A., Mills, A.S., Contos, M., Cotterell, A.H., Maluf, D., Posner, M.P. & Fisher, R.A. (2004). Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent C following liver transplantation. *Liver* 

Umeda, Y., Miyake, Y., Terada, R., Kobashi, H., Sakaguchi, K., Tanaka N. & Shiratori, Y. (2007). Short-term high dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after

transplantation setting: a European and an American perspective. *Liver* 

patients undergoing liver transplantation. *Liver Transplantation*, Vol.9, No. 11,

outcomes and should patients be retransplanted. *Clinics in Liver Disease*, Vol.12,

Parvaz, P., Werle, B., Trepo, C. & Zoulim, F. (2003). Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. *Journal of Hepatology*,

suppresses replication of hepatitis C virus genome in cultured hepatocytes.

Transplantation Society expert panel consensus conference on liver transplantation

Comprehensive analysis of risk factors associating with Hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. *British Journal* 

hepatitis B virus association cirrhosis. Liver Transplantation, Vol.14, Suppl. 2,
